Certara Reports Second Quarter 2025 Financial Results
RADNOR, PA— 2025 年 8 月 6 日-- Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug development,…
Certara2025 年 8 月 6 日
Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials
GSK shares real-world case studies on how Model-Based Meta-Analysis (MBMA) supports dose selection, virtual control…
Certara2025 年 7 月 31 日
Three Approaches to AI Adoption in Regulatory Writing
CoAuthor™ is a GenAI-driven regulatory writing platform, seamlessly integrated with Microsoft Word. By providing efficiency,…
Certara2025 年 7 月 23 日
How to Create a Data Validation Plan in Clinical Data Management
Download our guide to creating a data validation plan in clinical data management, the ultimate…
Certara2025 年 7 月 21 日
The Reference-scaled Average Bioequivalence (RSABE) Approach
We examine the Reference-scaled Average Bioequivalence (RSABE) approach for generic drug development and how it…
Certara2025 年 7 月 1 日
5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address
2025 年 6 月 30 日 Drug development is increasingly defined by its complexity. Teams must navigate rising…
Certara2025 年 6 月 30 日
Maintain & Adapt Pharma Market Access Digital Tools Using Feedback
Maintain the credibility of your pharma market access digital tools through continuous updates based on…
Certara2025 年 6 月 30 日
